NCT01669421View on ClinicalTrials.gov

Effect of Double Dose of Alpha 1-antitrypsin Augmentation Therapy on Lung Inflammation.

PHASE2CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

July 31, 2012

Primary Completion Date

May 31, 2016

Study Completion Date

May 31, 2016

Conditions
Alpha 1 Antitrypsin Deficiency
Interventions
DRUG

Alpha-1 Antitrypsin (human)

Comparison of Zemaira (Alpha 1 Antitrypsin Human) 120 mg/kg/weekly for four weeks versus 2 phases with same drug administered at standard doses of 60 mg/kg/weekly for four weeks each

Trial Locations (1)

33136

Division of Pulmonary and Critical Care, Human Reseach, U of Miami, Miami

Sponsors

Collaborators (1)

CSL Behring
All Listed Sponsors
collaborator

CSL Behring

INDUSTRY

lead

Michael Campos, MD

OTHER

NCT01669421 - Effect of Double Dose of Alpha 1-antitrypsin Augmentation Therapy on Lung Inflammation. | Biotech Hunter | Biotech Hunter